NewAmsterdam Pharma Co N.V.·4

Mar 10, 8:58 PM ET

LANGE LOUIS G 4

Research Summary

AI-generated summary

Updated

NewAmsterdam (NAMS) Director Louis G. Lange Sells Shares, Exercises Options

What Happened

  • Director Louis G. Lange sold 28,186 NewAmsterdam (NAMS) shares in an open-market disposition on 2026-03-06 for a weighted average price of $29.41, generating about $828,950.
  • On 2026-03-09 he exercised in-the-money options to acquire 44,619 shares at a strike price of $11.50 per share (cost ≈ $513,119). A corresponding derivative disposition at $0.00 was also reported for the same 44,619-share lot (see Context below).
  • The sale is a routine disposition; the option exercise resulted in a net increase of 16,433 shares held by the insider (44,619 acquired − 28,186 sold).

Key Details

  • Transaction dates and prices:
    • 2026-03-06: Sale (open market) 28,186 shares @ weighted avg $29.41 (range $29.03–$29.68) — proceeds ≈ $828,950. (Footnote F1)
    • 2026-03-09: Exercise of options to acquire 44,619 shares @ $11.50 — cost ≈ $513,119; derivative disposition reported at $0.00.
  • Net effect: +16,433 shares (44,619 acquired − 28,186 sold). Net cash received ≈ $315,831 (proceeds minus exercise cost).
  • Shares are held directly by LGLange III Trust DTD10 for the benefit of the reporting person (Footnote F2). The filing does not list the reporter’s total post-transaction share count in the provided excerpt.
  • Filing: Reported on 2026-03-10 for trades dated 2026-03-06 and 2026-03-09. Filing appears timely (not indicated as late).

Context

  • The 3/9 entries reflect an option exercise: the reporting person paid the strike price ($11.50) to acquire shares; the $0.00 derivative disposition indicates cancellation/conversion of the option instrument rather than an open-market sale of the newly acquired shares.
  • Sales can be routine (liquidity/tax reasons); exercises show the insider added shares to their position. This summary is factual and does not speculate on motivation.